Success Story: Advancing Cancer Treatment Research: Medicinal Therapeutics Expert Secures NIW Approval
Client’s Testimonial:
"I highly appreciate the attorney's guidance and support throughout my case filing. I am very grateful for their attentiveness to every single step. Thank you!"
On August 6th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Researcher in the Field of Medicinal Therapeutics (Approval Notice).
General Field: Medicinal Therapeutics
Position at the Time of Case Filing: Postdoctoral Researcher
Country of Origin: Pakistan
State of Residence at the Time of Filing: Michigan
Approval Notice Date: August 6th, 2026
Processing Time: 5 months, 17 days (Premium Processing Upgrade Requested)
Case Summary:
With a Ph.D. in Ecology/Biochemistry and Molecular Biology, the client has developed an extensive research record in medicinal therapeutics. Her work broadly explores biological processes involved in disease and potential approaches for improving treatment. Building on this background, she proposed continuing research aimed at better understanding cellular mechanisms associated with cancer and identifying promising directions for more targeted and individualized therapies. The client is currently conducting research at a U.S. university, where she applies advanced laboratory techniques to investigate these disease-related cellular processes.
In preparing her I-140 National Interest Waiver (NIW) petition, we emphasized the connection between this research and a significant healthcare challenge in the United States. Cancer imposes substantial health and economic burdens, while continued biomedical innovation remains important to improving treatment outcomes. We therefore demonstrated that the client's proposed endeavor could contribute to this broader national need by generating knowledge that may support therapeutic development and more precise approaches to patient care.
Her established research record also provided important evidence that she was well positioned to pursue this endeavor. The client had authored 23 peer-reviewed journal articles, including 4 first-authored papers, as well as 1 first-authored abstract and 3 book chapters. Her published research had accumulated 1,003 citations. Rather than presenting this citation total as sufficient by itself, we contextualized its significance through comparative evidence. Seven of her papers ranked among the top 10% most cited publications for their respective years, with another seven ranking among the top 20%. Independent researchers had also applied her findings in subsequent biomedical studies, demonstrating practical scholarly reliance on her work.
Professional trust provided another dimension to the case. The client had completed at least 21 peer reviews, showing that scholarly publications repeatedly relied on her expertise to evaluate the work of fellow researchers. Four recommendation letters further supported the record by explaining the value of her contributions and her ability to continue advancing research in the field.
“...it is clear that [Client’s] work is invaluable to her peers in translational biomedicine research.”
Taken together, her sustained publication record, substantial independent citation activity, peer-review service, documented influence on subsequent research, and ongoing U.S.-based work allowed us to demonstrate both past scientific impact and a credible path toward future contributions. We are pleased that her I-140 NIW petition was approved and wish the client continued success in advancing biomedical research with the potential to benefit U.S. healthcare.